Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb;50(1):251-256.
doi: 10.1007/s15010-021-01653-2. Epub 2021 Jul 5.

SARS-CoV-2 seroepidemiological study in healthcare workers and discordant results using seven different diagnostic methods

Elizabeth-Barbara Tatsi  1 , Charilaos Dellis  2 , Evangelia Petridou  3 , Kirkira Banou  3 , Levantia Zachariadou  3 , Vassiliki Syriopoulou  2 , Athanasios Michos  2
Affiliations

SARS-CoV-2 seroepidemiological study in healthcare workers and discordant results using seven different diagnostic methods

Elizabeth-Barbara Tatsi et al. Infection. 2022 Feb.

Abstract

The aim of the study was to access the SARS-CoV-2 antibody seroprevalence in healthcare workers (HCWs) of a tertiary pediatric hospital after the first wave of the pandemic and to compare the results among seven commercially available antibody detection assays, including chemiluminescence (CMIA), electroluminescence (ECLIA), Εnzyme-Linked Immunosorbent Assay (ELISA), and rapid immunochromatography (RIC). SARS-CoV-2 antibody detection was performed in serum samples of 1216 HCWs, using a reference CMIA assay and 8/1216 (0.66%) were detected positive. Positive serum samples were further tested with other assays; however, only one sample was positive by all tests. The rest 7 cases were negative with ECLIA and ELISA and gave discordant results with RIC test. Six months later, new serum samples of seropositive HCWs were analyzed with the same 7 tests, with inconsistent results again. Identification of reliable SARS-CoV-2 antibody tests is important to determine the actual number of past infections, the duration of antibodies, and guide public health decisions.

Keywords: Antibody; COVID-19; Comparison; Immunity; SARS-CoV-2; Serology.

PubMed Disclaimer

Conflict of interest statement

All authors declare no competing interests regarding the present study.

References

    1. WHO (2020) 'New-type coronavirus causes pneumonia in Wuhan: expert, Xinhua, China'; WHO. Coronavirus diseases (COVID-19), weekly operational update on COVID-19 (2020).
    1. Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, Tan KS, Wang DY, Yan Y. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res. 2020;7:11. - PMC - PubMed
    1. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;324:782–793. doi: 10.1001/jama.2020.12839. - DOI - PubMed
    1. Chu DK, Akl EA, Duda S, Solo K, Yaacoub S, Schunemannauthors C-SURGEs HJ. Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. Lancet. 2020;395:1973–1987. doi: 10.1016/S0140-6736(20)31142-9. - DOI - PMC - PubMed
    1. De Vito A, Geremia N, Fiore V, Princic E, Babudieri S, Madeddu G. Clinical features, laboratory findings and predictors of death in hospitalized patients with COVID-19 in Sardinia. Italy Eur Rev Med Pharmacol Sci. 2020;24:7861–7868. - PubMed

Substances